In the present study, it is interesting whether combining first-generation EGFR-TKI with Se/FO increases the in vivo anti-cancer efficacy over that of EGFR-TKI alone in NSCLC without the EGFR mutation, although the KRAS mutation inhibitor is currently available. This evidence concerns the gene EGFR and cancer.